Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease.
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease.

Picón-Pagès, Pol;Bonet, Jaume;García-García, Javier;Garcia-Buendia, Joan;Gutierrez, Daniela;Valle, Javier;Gómez-Casuso, Carmen E S;Sidelkivska, Valeriya;Alvarez, Alejandra;Perálvarez-Marín, Alex;Suades, Albert;Fernàndez-Busquets, Xavier;Andreu, David;Vicente, Rubén;Oliva, Baldomero;Muñoz, Francisco J;
computational and structural biotechnology journal 2019 Vol. 17 pp. 963-971
341
picnpags2019humancomputational

Abstract

Alzheimer's disease (AD) is a neurodegenerative process characterized by the accumulation of extracellular deposits of amyloid β-peptide (Aβ), which induces neuronal death. Monomeric Aβ is not toxic but tends to aggregate into β-sheets that are neurotoxic. Therefore to prevent or delay AD onset and progression one of the main therapeutic approaches would be to impair Aβ assembly into oligomers and fibrils and to promote disaggregation of the preformed aggregate. Albumin is the most abundant protein in the cerebrospinal fluid and it was reported to bind Aβ impeding its aggregation. In a previous work we identified a 35-residue sequence of clusterin, a well-known protein that binds Aβ, that is highly similar to the C-terminus (CTerm) of albumin. In this work, the docking experiments show that the average binding free energy of the CTerm-Aβ simulations was significantly lower than that of the clusterin-Aβ binding, highlighting the possibility that the CTerm retains albumin's binding properties. To validate this observation, we performed structural analysis of soluble and aggregated 1 μM Aβ incubated with 5 μM CTerm, equimolar to the albumin concentration in the CSF. Reversed-phase chromatography and electron microscopy analysis demonstrated a reduction of Aβ aggregates when the CTerm was present. Furthermore, we treated a human neuroblastoma cell line with soluble and aggregated Aβ incubated with CTerm obtaining a significant protection against Aβ-induced neurotoxicity. These and data suggest that the albumin CTerm is able to impair Aβ aggregation and to promote disassemble of Aβ aggregates protecting neurons.

Keywords

Docking amyloid alzheimer's disease albumin tfa, trifluoroacetic acid uv, ultraviolet hplc, high performance liquid chromatography ad, alzheimer's disease app, amyloid precursor protein aß, amyloid-ß peptide cd, circular dichroism csf, cerebrospinal fluid cterm, albumin c-terminus lc-ms, liquid chromatography-mass spectrometry mtt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide nmr, nuclear magnetic resonance pbs, phosphate-buffered saline pdb, protein data bank ppi, protein-protein interactions sds, sodium dodecyl sulfate tem, transmission electron microscopy faβ1–42, hilyte fluor488 labelled human aβ1–42 β-sheet

Access

DOI:
10.1016/j.csbj.2019.06.017

Citation

ID: 67153
Ref Key: picnpags2019humancomputational
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
67153
Unique Identifier:
10.1016/j.csbj.2019.06.017
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store